Moderna (MRNA) Conquers New Highs


During the last session 32M of Moderna, Inc.’s (NasdaqGS:MRNA) shares were traded. The stock closed at $419.05 per share indicating that it gained $32.54 or 8.42% during that day which brings the Moderna, Inc.’s valuation to $168.26B.

The 52-week high for the Moderna, Inc.’s shares is $433.00. That puts it -3.22% from that peak but still a massive gain since the share price dropped to a 52-week low of $54.21, while the S&P 500’s share price change was of 33%.

The company currently has a 280.86 P/E ratio and a price target of $184.92.

What does the trading volume tell us about the MRNA stock?

During the last trading session, Moderna, Inc. (NasdaqGS:MRNA) has seen growth in its daily volume. The daily volume was of 13M, while in the last 10 days the average was 15.59M and last three months – 13.03M.

The increasing interest in the MRNA stock from the investors is helping to drive the stock price up.


Shrinking short interest

The Moderna, Inc.’s shares are seeing a decreasing short interest compared to the previous month. As of today, there are 11.83M shares being shorted which translates into 1.27 of a short ratio for MRNA, while in the previous month the shorted shares were 12.94M.

Moderna, Inc. (NasdaqGS:MRNA)’s financials

With a market cap of 168.26B, Moderna, Inc. holds a total cash of $7.74B that translates into $19.26 per share, while the total debt is of $279M.

The company has seen a decrease in the revenue with a year-over-year quarterly revenue growth percentage of 24,112.50%. The current revenue is of $2.73B that is $6.95 per share.

This is a ridiculously good sign for the future.